| Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT (NCT05628922) | Fudan University | 2022-07-02 |
| Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer (NCT05261750) | PT. Prodia Stem Cell Indonesia | 2022-04-30 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors (NCT05070247) | Takeda | 2022-04-14 |
| Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer (NCT05305131) | National University Hospital, Singapore | 2022-03-28 |
| A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China (NCT05638269) | Zhujiang Hospital | 2022-03-01 |
| Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies (NCT04925544) | Stanford University | 2022-01-25 |
| Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment (NCT04875611) | Maria Sklodowska-Curie National Research Institute of Oncology | 2021-08-26 |
| Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy (NCT04978012) | Fudan University | 2021-07-25 |
| Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer (NCT05564286) | Shantou University Medical College | 2021-07-01 |
| Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma (NCT04453826) | Sun Yat-sen University | 2020-09-01 |
| Somatostatin Receptor Imaging in NPC, EBV Related Cancers (NCT05581550) | National Cancer Centre, Singapore | 2020-06-29 |
| Applying PET/MR in Oncology - a Prospective Project (NCT04158414) | Tel-Aviv Sourasky Medical Center | 2019-11-28 |
| Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (NCT03682055) | Cullinan Therapeutics Inc. | 2019-04-04 |
| Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma (NCT04004871) | Guangxi Medical University | 2019-03-28 |
| The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma (NCT06268600) | Jiangxi Provincial Cancer Hospital | 2019-01-01 |
| Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI (NCT03656250) | NYU Langone Health | 2017-11-18 |
| Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT03282617) | National University Hospital, Singapore | 2017-08-14 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies (NCT03144661) | Incyte Corporation | 2017-05-25 |
| A Study of Nasopharyngeal Carcinoma From Guangdong (NCT03003182) | Sun Yat-sen University | 2017-05-10 |
| Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions (NCT03129412) | Zhejiang Cancer Hospital | 2017-04-14 |
| Cell-free Tumor DNA in Head and Neck Cancer Patients (NCT03942380) | Christian von Buchwald | 2017-02-01 |
| Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer (NCT02875613) | Assuntina Sacco, M.D. | 2017-01-01 |
| Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients (NCT04340024) | National Cancer Centre, Singapore | 2015-09-30 |
| Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NCT02507154) | National University Hospital, Singapore | 2015-07-01 |
| Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors (NCT02080416) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-07-01 |
| Integrated Cancer Repository for Cancer Research (NCT02012699) | University of Nebraska | 2013-11-01 |
| A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma (NCT01800071) | Cancer Research UK | 2013-03-01 |
| Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy (NCT01937793) | National Taiwan University Hospital | 2013-01-01 |
| Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC (NCT03890185) | King Faisal Specialist Hospital & Research Center | 2012-10-01 |
| Assessment of New Radiation Oncology Technologies and Treatments (NCT01379872) | Trans Tasman Radiation Oncology Group | 2011-06-01 |
| Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography (NCT01347424) | Sun Yat-sen University | 2011-01-01 |
| 124I-FIAU Imaging in EBV and KSHV Associated Cancers (NCT00982449) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2010-12-01 |
| Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy (NCT01094405) | Chinese University of Hong Kong | 2010-03-31 |
| Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer (NCT01074021) | Biotech Pharmaceutical Co., Ltd. | 2009-10-01 |
| A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer (NCT00943891) | National University Hospital, Singapore | 2008-07-01 |
| Cluster Randomized Controlled Screening Trial for NPC (NCT00941538) | Sun Yat-sen University | 2008-01-01 |
| Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer (NCT00706316) | University Health Network, Toronto | 2007-12-01 |
| A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. (NCT00439426) | Hoffmann-La Roche | 2007-04-01 |
| Acupuncture for Prevention of Radiation-Induced Xerostomia (NCT00430378) | M.D. Anderson Cancer Center | 2007-01-01 |
| A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy (NCT00370890) | Chinese University of Hong Kong | 2006-09-04 |
| Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer (NCT01312311) | Samsung Medical Center | 2006-07-01 |
| A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer (NCT00603915) | University Health Network, Toronto | 2006-06-01 |
| Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients (NCT00304694) | National Taiwan University Hospital | 2006-03-01 |
| To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer (NCT00697619) | Sun Yat-sen University | 2005-09-01 |
| A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer (NCT02608073) | Hoffmann-La Roche | 2004-11-01 |
| EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (NCT00078546) | Baylor College of Medicine | 2003-09-01 |
| Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma (NCT03175939) | Sun Yat-sen University | 1998-04-01 |
| Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers (NCT00141765) | University of Michigan Rogel Cancer Center | 1997-01-01 |